Douglas B Cines Selected Research

Urokinase-Type Plasminogen Activator (Urokinase)

12/2017	Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
2/2016	A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.
4/2015	Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.
9/2013	Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
11/2011	Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.
7/2011	Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
12/2010	Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.
6/2010	Induction of tissue factor by urokinase in lung epithelial cells and in the lungs.
3/2009	Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
3/2009	uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas B Cines Research Topics

Disease

49	Thrombocytopenia (Thrombopenia) 10/2022 - 02/2002
40	Thrombosis (Thrombus) 01/2021 - 02/2002
30	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 10/2022 - 08/2002
23	Hemorrhage 01/2021 - 08/2003
18	Inflammation (Inflammations) 01/2022 - 05/2003
11	Stroke (Strokes) 01/2019 - 09/2006
10	Infections 01/2021 - 12/2003
10	Ischemia 08/2017 - 02/2008
9	Hypotension (Low Blood Pressure) 01/2018 - 09/2008
8	Neoplasms (Cancer) 12/2017 - 05/2003
8	Acute Lung Injury 02/2017 - 10/2006
8	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2015 - 09/2004
7	Hypoxia (Hypoxemia) 02/2014 - 10/2005
6	Brain Injuries (Brain Injury) 09/2011 - 09/2004
5	Atherosclerosis 01/2020 - 05/2002
4	COVID-19 01/2022 - 05/2020
4	Thrombotic Thrombocytopenic Purpura 12/2017 - 11/2012
4	Vascular System Injuries 05/2015 - 06/2004
4	Hypercapnia 11/2011 - 09/2008
3	Thromboembolism 11/2020 - 11/2016
3	Pre-Eclampsia (Preeclampsia) 01/2020 - 11/2017
3	Hemolysis 01/2020 - 06/2007
3	Venous Thromboembolism 01/2020 - 02/2012
3	Ischemic Stroke 01/2019 - 04/2010
3	Thrombotic Microangiopathies 12/2017 - 09/2013
3	acquired Thrombotic thrombocytopenic purpura 01/2016 - 01/2016
3	Purpura 01/2016 - 11/2008
3	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 07/2010 - 10/2005
3	Lung Injury 06/2010 - 05/2003
3	Neoplasm Metastasis (Metastasis) 03/2007 - 02/2006
3	Pathologic Processes 10/2006 - 10/2002
2	Disease Progression 01/2021 - 07/2010
2	Sepsis (Septicemia) 01/2021 - 10/2012
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020 - 11/2012
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2020 - 01/2013
2	Necrosis 01/2019 - 01/2018
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018 - 08/2003
2	Carcinogenesis 12/2017 - 03/2007
2	Atypical Hemolytic Uremic Syndrome 12/2017 - 11/2017
2	Reperfusion Injury 01/2017 - 08/2009
2	Autoimmune Diseases (Autoimmune Disease) 07/2016 - 02/2007

Drug/Important Bio-Agent (IBA)

37	Heparin (Liquaemin)FDA LinkGeneric 11/2021 - 02/2002
23	Inosine Triphosphate (ITP)IBA 10/2022 - 08/2002
22	Platelet Factor 4IBA 11/2021 - 02/2002
22	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2017 - 10/2002
21	AntibodiesIBA 11/2021 - 02/2002
18	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 10/2002
18	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019 - 09/2004
12	Proteins (Proteins, Gene)FDA Link 08/2017 - 10/2002
10	AutoantibodiesIBA 01/2016 - 08/2002
9	FibrinIBA 01/2019 - 08/2003
7	AntigensIBA 11/2021 - 02/2007
7	Antigen-Antibody Complex (Immune Complex)IBA 11/2021 - 01/2009
7	Pharmaceutical PreparationsIBA 01/2019 - 05/2003
6	Immunoglobulin G (IgG)IBA 11/2021 - 02/2007
6	N-Methylaspartate (NMDA)IBA 01/2019 - 05/2005
6	GlycosaminoglycansIBA 07/2016 - 06/2004
5	Monoclonal AntibodiesIBA 01/2022 - 02/2002
5	Phosphotransferases (Kinase)IBA 01/2018 - 03/2009
5	Thrombopoietin ReceptorsIBA 12/2017 - 11/2008
5	von Willebrand FactorIBA 01/2016 - 12/2011
5	Peptides (Polypeptides)IBA 01/2016 - 08/2004
5	Urokinase Plasminogen Activator ReceptorsIBA 02/2009 - 05/2003
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 10/2006
4	alpha-DefensinsIBA 01/2021 - 08/2004
4	Mitogen-Activated Protein KinasesIBA 01/2019 - 03/2009
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2019 - 11/2013
4	ChemokinesIBA 01/2018 - 06/2004
4	Rituximab (Mabthera)FDA Link 12/2017 - 08/2012
4	ThrombomodulinIBA 08/2017 - 08/2009
4	Thrombin FDA Link 11/2016 - 02/2007
4	thiamine triphosphorate (TTP)IBA 01/2016 - 05/2015
3	DefensinsIBA 01/2021 - 02/2016
3	Complement System Proteins (Complement)IBA 01/2021 - 09/2013
3	oxidized low density lipoproteinIBA 01/2020 - 05/2002
3	AnticoagulantsIBA 11/2019 - 11/2004
3	Endothelin-1 (Endothelin 1)IBA 01/2019 - 02/2014
3	Thromboplastin (Tissue Factor)IBA 08/2017 - 02/2008
3	romiplostim FDA Link 01/2017 - 11/2008
3	ProdrugsIBA 02/2016 - 11/2009
3	Hemostatics (Antihemorrhagics)IBA 02/2016 - 08/2003
3	Glutamic Acid (Glutamate)FDA Link 01/2016 - 03/2011
3	PlasminogenIBA 01/2016 - 05/2003
3	Protamines (Protamine Sulfate)FDA Link 04/2013 - 11/2004
3	Plasminogen InactivatorsIBA 09/2011 - 09/2006
2	butyl phosphorotrithioate (DEF)IBA 01/2022 - 02/2016
2	Plasminogen Activator Inhibitor 1IBA 01/2021 - 05/2003
2	LipidsIBA 01/2020 - 02/2016
2	EnzymesIBA 01/2020 - 11/2012
2	CholesterolIBA 01/2020 - 02/2016
2	cyclo(Trp-Asp-Pro-Val-Leu)IBA 01/2019 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 12/2018 - 09/2014
2	anticomplementIBA 12/2017 - 11/2017
2	Single-Chain AntibodiesIBA 01/2017 - 06/2007
2	Protein CIBA 01/2017 - 09/2011
2	AutoantigensIBA 07/2016 - 02/2007
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 02/2016 - 08/2003

Therapy/Procedure

19	Therapeutics 01/2021 - 02/2002
6	Splenectomy 10/2022 - 01/2004
3	Thrombolytic Therapy 01/2021 - 08/2009